Global Blood Therapeutics (GBT, www.globalbloodtx.com), based in SSF, is a clinical stage biopharmaceutical company developing novel small molecule therapeutics to treat grievous, non-malignant blood-based conditions for which there are currently only limited therapy.

GBT440, our lead drug candidate, is a potential once daily oral prophylactic therapy for patients with sickle cell disease (SCD). By disrupting the fundamental pathophysiology of SCD, GBT440 has the potential to halt red blood cell sickling & disease progression, which could fundamentally transform lives of SCD patients. Phase I/II study is ongoing; proof of concept demonstrated 8/2015 which was basis of GBT's IPO.

GBT has a pipeline of research programs addressing additional blood disorders. GBT is currently identifying small molecule leads for an orally administered prophylactic treatment of hereditary angioedema. Also, we are developing GBT440 and possibly GBT440 analogues for acute & chronic hypoxemic lung diseases.